Hutchmed China Ltd - Company Profile and SWOT Analysis
SummaryHutchmed China Ltd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Hutchmed China Ltd (Hutchmed) is a biopharmaceutical company that manufactures, discovers, develops, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. Major products include fruquintinib, an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3; surufatinib, a novel, oral angio-immuno kinase inhibitor that inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR); and savolitinib, an oral selective MET TKI that blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations. It operates in China, North America, Europe, and Australia. The company offers prescription and consumer health drugs to hospitals and through other pharmaceutical companies under the brand names Elunate, Sulanda, and Orpathys, respectively. Hutchmed is headquartered in Hong Kong.
Scope
- Detailed information on Hutchmed China Ltd required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Hutchmed China Ltd in the form of a SWOT analysis
- An in-depth view of the business model of Hutchmed China Ltd including a breakdown and examination of key business segments
- Intelligence on Hutchmed China Ltd's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Hutchmed China Ltd, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons To Buy
- Gain understanding of Hutchmed China Ltd and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Hutchmed China Ltd as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Hutchmed China Ltd's business structure, strategy and prospects.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.